ProQR Therapeutics N.V. (PRQR) vs Sionna Therapeutics (SION)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
ProQR Therapeutics N.V. (PRQR) has outperformed Sionna Therapeutics (SION) over the past year, losing 33.5% versus a loss of 82.8%. ProQR Therapeutics N.V. is the larger company by market cap ($225.1 million vs $220.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PRQR | SION |
|---|---|---|
| Share price | $1.60 | $4.88 |
| Market cap | $225.08M | $220.11M |
| 1-day change | +1.59% | -0.51% |
| YTD return | -22.28% | -88.09% |
| 1-year return | -33.47% | -82.81% |
| 5-year return | -80.08% | — |
| EPS (TTM) | $-0.45 | $-2.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.10 | $54.97 |
| 52-week low | $1.33 | $4.01 |
| Distance from 52-week high | -48.55% | -91.13% |
| Analyst consensus | strong_buy | hold |
| Avg. price target upside | +387.77% | +330.77% |
| Average volume | 796.41K | 2.19M |
| Shares outstanding | 141.12M | 45.15M |
| Employees | 186 | 59 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PRQR has outperformed SION by 49.3 percentage points over the past year.
About ProQR Therapeutics N.V.
PRQR stock →ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs.
Health Care · Biotechnology: Pharmaceutical Preparations · 186 employees
About Sionna Therapeutics
SION stock →Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial.
Health Care · Biotechnology: Pharmaceutical Preparations · 59 employees
PRQR vs SION FAQ
Which is bigger, ProQR Therapeutics N.V. or Sionna Therapeutics?
ProQR Therapeutics N.V. (PRQR) is larger, with a market capitalization of $225.08M compared with $220.11M for Sionna Therapeutics (SION).
Which stock has performed better over the past year, PRQR or SION?
PRQR returned -33.47% over the past 12 months, compared with -82.81% for SION (price return, excluding dividends). Past performance does not predict future results.
Are ProQR Therapeutics N.V. and Sionna Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.